Chlorogen Inc., a St. Louis-based developer of a protein-based therapy for gynecological cancer, has ceased operations, and is in the process of selling its technology assets. The company had raised over $15 million in VC funding from firms like Finistere P
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.